nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—KCNH2—purkinje fiber—dilated cardiomyopathy	0.154	0.467	CbGeAlD
Ondansetron—KCNH2—endocardium—dilated cardiomyopathy	0.0796	0.241	CbGeAlD
Ondansetron—CYP2C9—cardial valve—dilated cardiomyopathy	0.0647	0.196	CbGeAlD
Ondansetron—Local reaction—Furosemide—dilated cardiomyopathy	0.0135	0.03	CcSEcCtD
Ondansetron—Ear disorder—Lisinopril—dilated cardiomyopathy	0.0104	0.0231	CcSEcCtD
Ondansetron—Blindness—Lisinopril—dilated cardiomyopathy	0.0101	0.0225	CcSEcCtD
Ondansetron—Sleep disturbance—Lisinopril—dilated cardiomyopathy	0.00997	0.0223	CcSEcCtD
Ondansetron—Injection site pain—Furosemide—dilated cardiomyopathy	0.00912	0.0204	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00895	0.02	CcSEcCtD
Ondansetron—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00871	0.0194	CcSEcCtD
Ondansetron—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00766	0.0171	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00759	0.0169	CcSEcCtD
Ondansetron—SLC47A1—heart—dilated cardiomyopathy	0.00717	0.0217	CbGeAlD
Ondansetron—KCNH2—cardiac ventricle—dilated cardiomyopathy	0.0067	0.0203	CbGeAlD
Ondansetron—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.0065	0.0145	CcSEcCtD
Ondansetron—KCNH2—myocardium—dilated cardiomyopathy	0.0063	0.0191	CbGeAlD
Ondansetron—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.00619	0.0138	CcSEcCtD
Ondansetron—Swelling—Furosemide—dilated cardiomyopathy	0.00613	0.0137	CcSEcCtD
Ondansetron—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.00566	0.0126	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00559	0.0125	CcSEcCtD
Ondansetron—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00555	0.0124	CcSEcCtD
Ondansetron—Malaise—Spironolactone—dilated cardiomyopathy	0.0054	0.012	CcSEcCtD
Ondansetron—Urinary retention—Furosemide—dilated cardiomyopathy	0.00514	0.0115	CcSEcCtD
Ondansetron—Discomfort—Spironolactone—dilated cardiomyopathy	0.00503	0.0112	CcSEcCtD
Ondansetron—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00492	0.011	CcSEcCtD
Ondansetron—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00488	0.0109	CcSEcCtD
Ondansetron—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00487	0.0109	CcSEcCtD
Ondansetron—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00469	0.0105	CcSEcCtD
Ondansetron—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00451	0.0101	CcSEcCtD
Ondansetron—KCNH2—heart—dilated cardiomyopathy	0.0044	0.0133	CbGeAlD
Ondansetron—Somnolence—Spironolactone—dilated cardiomyopathy	0.00434	0.00969	CcSEcCtD
Ondansetron—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00428	0.00956	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00422	0.00941	CcSEcCtD
Ondansetron—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00419	0.00936	CcSEcCtD
Ondansetron—Drowsiness—Furosemide—dilated cardiomyopathy	0.00417	0.0093	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00413	0.00922	CcSEcCtD
Ondansetron—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00403	0.00898	CcSEcCtD
Ondansetron—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00394	0.0088	CcSEcCtD
Ondansetron—Urticaria—Spironolactone—dilated cardiomyopathy	0.00388	0.00866	CcSEcCtD
Ondansetron—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00386	0.00862	CcSEcCtD
Ondansetron—KCNH2—cardiac atrium—dilated cardiomyopathy	0.00376	0.0114	CbGeAlD
Ondansetron—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00365	0.00815	CcSEcCtD
Ondansetron—Visual impairment—Furosemide—dilated cardiomyopathy	0.0036	0.00805	CcSEcCtD
Ondansetron—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.0036	0.00803	CcSEcCtD
Ondansetron—CYP2C9—heart—dilated cardiomyopathy	0.00357	0.0108	CbGeAlD
Ondansetron—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00354	0.00789	CcSEcCtD
Ondansetron—Asthma—Lisinopril—dilated cardiomyopathy	0.00351	0.00783	CcSEcCtD
Ondansetron—Eye disorder—Furosemide—dilated cardiomyopathy	0.0035	0.0078	CcSEcCtD
Ondansetron—Pruritus—Spironolactone—dilated cardiomyopathy	0.00346	0.00771	CcSEcCtD
Ondansetron—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00345	0.0077	CcSEcCtD
Ondansetron—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00342	0.00762	CcSEcCtD
Ondansetron—Angiopathy—Furosemide—dilated cardiomyopathy	0.00339	0.00758	CcSEcCtD
Ondansetron—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00338	0.00754	CcSEcCtD
Ondansetron—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00334	0.00746	CcSEcCtD
Ondansetron—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00334	0.00746	CcSEcCtD
Ondansetron—Dysuria—Lisinopril—dilated cardiomyopathy	0.00328	0.00732	CcSEcCtD
Ondansetron—Erythema—Furosemide—dilated cardiomyopathy	0.00326	0.00727	CcSEcCtD
Ondansetron—Dizziness—Spironolactone—dilated cardiomyopathy	0.00323	0.00721	CcSEcCtD
Ondansetron—Flatulence—Furosemide—dilated cardiomyopathy	0.00321	0.00716	CcSEcCtD
Ondansetron—Vomiting—Spironolactone—dilated cardiomyopathy	0.00311	0.00693	CcSEcCtD
Ondansetron—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.0031	0.00692	CcSEcCtD
Ondansetron—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00308	0.00688	CcSEcCtD
Ondansetron—Rash—Spironolactone—dilated cardiomyopathy	0.00308	0.00687	CcSEcCtD
Ondansetron—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00308	0.00687	CcSEcCtD
Ondansetron—Vision blurred—Furosemide—dilated cardiomyopathy	0.00307	0.00685	CcSEcCtD
Ondansetron—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00306	0.00684	CcSEcCtD
Ondansetron—Headache—Spironolactone—dilated cardiomyopathy	0.00306	0.00683	CcSEcCtD
Ondansetron—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00304	0.00678	CcSEcCtD
Ondansetron—Agitation—Furosemide—dilated cardiomyopathy	0.00299	0.00668	CcSEcCtD
Ondansetron—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00296	0.0066	CcSEcCtD
Ondansetron—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00286	0.00638	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00275	0.00615	CcSEcCtD
Ondansetron—Dry mouth—Furosemide—dilated cardiomyopathy	0.00271	0.00605	CcSEcCtD
Ondansetron—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00266	0.00593	CcSEcCtD
Ondansetron—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00265	0.00592	CcSEcCtD
Ondansetron—Shock—Furosemide—dilated cardiomyopathy	0.00261	0.00584	CcSEcCtD
Ondansetron—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00261	0.00582	CcSEcCtD
Ondansetron—Flushing—Lisinopril—dilated cardiomyopathy	0.0026	0.00581	CcSEcCtD
Ondansetron—Skin disorder—Furosemide—dilated cardiomyopathy	0.00258	0.00576	CcSEcCtD
Ondansetron—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00255	0.00568	CcSEcCtD
Ondansetron—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00253	0.00565	CcSEcCtD
Ondansetron—Chills—Lisinopril—dilated cardiomyopathy	0.00252	0.00562	CcSEcCtD
Ondansetron—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00251	0.0056	CcSEcCtD
Ondansetron—Hypotension—Furosemide—dilated cardiomyopathy	0.00248	0.00554	CcSEcCtD
Ondansetron—Erythema—Lisinopril—dilated cardiomyopathy	0.00244	0.00545	CcSEcCtD
Ondansetron—Flatulence—Lisinopril—dilated cardiomyopathy	0.00241	0.00537	CcSEcCtD
Ondansetron—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00239	0.00533	CcSEcCtD
Ondansetron—Somnolence—Furosemide—dilated cardiomyopathy	0.00236	0.00527	CcSEcCtD
Ondansetron—Vision blurred—Lisinopril—dilated cardiomyopathy	0.0023	0.00514	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00229	0.00512	CcSEcCtD
Ondansetron—Fatigue—Furosemide—dilated cardiomyopathy	0.00229	0.00511	CcSEcCtD
Ondansetron—Tremor—Lisinopril—dilated cardiomyopathy	0.00229	0.00511	CcSEcCtD
Ondansetron—Constipation—Furosemide—dilated cardiomyopathy	0.00227	0.00507	CcSEcCtD
Ondansetron—Pain—Furosemide—dilated cardiomyopathy	0.00227	0.00507	CcSEcCtD
Ondansetron—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00227	0.00506	CcSEcCtD
Ondansetron—Angioedema—Lisinopril—dilated cardiomyopathy	0.00223	0.00498	CcSEcCtD
Ondansetron—Malaise—Lisinopril—dilated cardiomyopathy	0.0022	0.00492	CcSEcCtD
Ondansetron—Syncope—Lisinopril—dilated cardiomyopathy	0.00219	0.00489	CcSEcCtD
Ondansetron—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00219	0.00489	CcSEcCtD
Ondansetron—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.00217	0.00485	CcSEcCtD
Ondansetron—Palpitations—Lisinopril—dilated cardiomyopathy	0.00216	0.00482	CcSEcCtD
Ondansetron—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00215	0.00479	CcSEcCtD
Ondansetron—Cough—Lisinopril—dilated cardiomyopathy	0.00213	0.00476	CcSEcCtD
Ondansetron—Urticaria—Furosemide—dilated cardiomyopathy	0.00211	0.00471	CcSEcCtD
Ondansetron—Abdominal pain—Furosemide—dilated cardiomyopathy	0.0021	0.00469	CcSEcCtD
Ondansetron—Body temperature increased—Furosemide—dilated cardiomyopathy	0.0021	0.00469	CcSEcCtD
Ondansetron—Chest pain—Lisinopril—dilated cardiomyopathy	0.00208	0.00464	CcSEcCtD
Ondansetron—Anxiety—Lisinopril—dilated cardiomyopathy	0.00207	0.00463	CcSEcCtD
Ondansetron—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00207	0.00461	CcSEcCtD
Ondansetron—Discomfort—Lisinopril—dilated cardiomyopathy	0.00205	0.00459	CcSEcCtD
Ondansetron—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00203	0.00454	CcSEcCtD
Ondansetron—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00199	0.00445	CcSEcCtD
Ondansetron—Shock—Lisinopril—dilated cardiomyopathy	0.00196	0.00438	CcSEcCtD
Ondansetron—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00196	0.00437	CcSEcCtD
Ondansetron—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00195	0.00434	CcSEcCtD
Ondansetron—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00194	0.00432	CcSEcCtD
Ondansetron—Asthenia—Furosemide—dilated cardiomyopathy	0.00191	0.00426	CcSEcCtD
Ondansetron—Pruritus—Furosemide—dilated cardiomyopathy	0.00188	0.0042	CcSEcCtD
Ondansetron—Hypotension—Lisinopril—dilated cardiomyopathy	0.00186	0.00416	CcSEcCtD
Ondansetron—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00182	0.00406	CcSEcCtD
Ondansetron—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00179	0.004	CcSEcCtD
Ondansetron—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00178	0.00397	CcSEcCtD
Ondansetron—Somnolence—Lisinopril—dilated cardiomyopathy	0.00177	0.00396	CcSEcCtD
Ondansetron—Dizziness—Furosemide—dilated cardiomyopathy	0.00176	0.00392	CcSEcCtD
Ondansetron—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00172	0.00384	CcSEcCtD
Ondansetron—Fatigue—Lisinopril—dilated cardiomyopathy	0.00172	0.00384	CcSEcCtD
Ondansetron—Pain—Lisinopril—dilated cardiomyopathy	0.00171	0.00381	CcSEcCtD
Ondansetron—Constipation—Lisinopril—dilated cardiomyopathy	0.00171	0.00381	CcSEcCtD
Ondansetron—Vomiting—Furosemide—dilated cardiomyopathy	0.00169	0.00377	CcSEcCtD
Ondansetron—Rash—Furosemide—dilated cardiomyopathy	0.00168	0.00374	CcSEcCtD
Ondansetron—Dermatitis—Furosemide—dilated cardiomyopathy	0.00167	0.00374	CcSEcCtD
Ondansetron—Headache—Furosemide—dilated cardiomyopathy	0.00166	0.00372	CcSEcCtD
Ondansetron—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00164	0.00367	CcSEcCtD
Ondansetron—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00163	0.00364	CcSEcCtD
Ondansetron—Urticaria—Lisinopril—dilated cardiomyopathy	0.00158	0.00354	CcSEcCtD
Ondansetron—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00158	0.00352	CcSEcCtD
Ondansetron—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00158	0.00352	CcSEcCtD
Ondansetron—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00147	0.00328	CcSEcCtD
Ondansetron—Asthenia—Lisinopril—dilated cardiomyopathy	0.00143	0.00319	CcSEcCtD
Ondansetron—Pruritus—Lisinopril—dilated cardiomyopathy	0.00141	0.00315	CcSEcCtD
Ondansetron—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00136	0.00305	CcSEcCtD
Ondansetron—Dizziness—Lisinopril—dilated cardiomyopathy	0.00132	0.00294	CcSEcCtD
Ondansetron—Vomiting—Lisinopril—dilated cardiomyopathy	0.00127	0.00283	CcSEcCtD
Ondansetron—Rash—Lisinopril—dilated cardiomyopathy	0.00126	0.00281	CcSEcCtD
Ondansetron—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00126	0.0028	CcSEcCtD
Ondansetron—Headache—Lisinopril—dilated cardiomyopathy	0.00125	0.00279	CcSEcCtD
Ondansetron—HTR4—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000551	0.00249	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—AGTR1—dilated cardiomyopathy	0.000541	0.00244	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000535	0.00242	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000535	0.00242	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.000528	0.00239	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000527	0.00238	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.000512	0.00231	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.000512	0.00231	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000512	0.00231	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000512	0.00231	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.0005	0.00226	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.0005	0.00226	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000497	0.00225	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000496	0.00224	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000496	0.00224	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000492	0.00222	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000481	0.00217	CbGpPWpGaD
Ondansetron—OPRM1—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.00048	0.00217	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00048	0.00217	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000476	0.00215	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000475	0.00215	CbGpPWpGaD
Ondansetron—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000473	0.00214	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000472	0.00213	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000472	0.00213	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000465	0.0021	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000458	0.00207	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000455	0.00206	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.00045	0.00203	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.000442	0.002	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000439	0.00198	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000428	0.00193	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000425	0.00192	CbGpPWpGaD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000425	0.00192	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000423	0.00191	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000423	0.00191	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000411	0.00186	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000407	0.00184	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000407	0.00184	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000407	0.00184	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000407	0.00184	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000402	0.00181	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000402	0.00181	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000401	0.00181	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00039	0.00176	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000385	0.00174	CbGpPWpGaD
Ondansetron—OPRM1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000381	0.00172	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000379	0.00171	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000379	0.00171	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000367	0.00166	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000367	0.00166	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000366	0.00165	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000365	0.00165	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000364	0.00164	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000363	0.00164	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000359	0.00162	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000359	0.00162	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000347	0.00157	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000344	0.00155	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000342	0.00155	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000334	0.00151	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000333	0.0015	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000324	0.00146	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000322	0.00145	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000321	0.00145	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000313	0.00141	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000313	0.00141	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000312	0.00141	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.00031	0.0014	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.00031	0.0014	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000308	0.00139	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—ANKRD1—dilated cardiomyopathy	0.000299	0.00135	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000298	0.00135	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000297	0.00134	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000297	0.00134	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000295	0.00133	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000295	0.00133	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000293	0.00132	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000289	0.00131	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000288	0.0013	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000283	0.00128	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—TAZ—dilated cardiomyopathy	0.000281	0.00127	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000279	0.00126	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000278	0.00126	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000277	0.00125	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000276	0.00125	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000275	0.00124	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000275	0.00124	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000274	0.00124	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000271	0.00122	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—RAF1—dilated cardiomyopathy	0.000267	0.00121	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000266	0.0012	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000262	0.00118	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000255	0.00115	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—SDHA—dilated cardiomyopathy	0.000255	0.00115	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000238	0.00108	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.00023	0.00104	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.00023	0.00104	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000227	0.00103	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000226	0.00102	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00022	0.000996	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.00022	0.000995	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000217	0.000979	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—ANKRD1—dilated cardiomyopathy	0.000216	0.000977	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000216	0.000974	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000214	0.000966	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000211	0.000953	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000211	0.000953	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000209	0.000944	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000209	0.000944	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000207	0.000937	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000207	0.000936	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—TAZ—dilated cardiomyopathy	0.000204	0.000921	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—TAZ—dilated cardiomyopathy	0.000203	0.000919	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000203	0.000917	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000203	0.000917	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000201	0.000908	CbGpPWpGaD
Ondansetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000201	0.000908	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000194	0.000878	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000194	0.000877	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000189	0.000853	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000188	0.00085	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000188	0.000848	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000185	0.000837	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000184	0.000833	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000184	0.000833	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—SDHA—dilated cardiomyopathy	0.000184	0.000833	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—SDHA—dilated cardiomyopathy	0.000184	0.000831	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000183	0.000826	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000177	0.000799	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000175	0.000792	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000175	0.000792	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000174	0.000788	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000171	0.000774	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000168	0.000758	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000168	0.000758	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000167	0.000756	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000166	0.00075	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000163	0.000736	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000161	0.000726	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—AGT—dilated cardiomyopathy	0.00016	0.000722	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000159	0.000719	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000159	0.000719	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000158	0.000713	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000156	0.000705	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	0.000154	0.000695	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000153	0.000689	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000152	0.000689	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000148	0.000669	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000148	0.000668	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	0.000145	0.000653	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000143	0.000648	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000143	0.000647	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000142	0.00064	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000139	0.000628	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000135	0.000609	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000135	0.000608	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	0.000131	0.000591	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.00013	0.000589	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00013	0.000589	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.00013	0.000586	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000129	0.000582	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000128	0.000578	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000125	0.000562	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000123	0.000558	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000123	0.000558	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000123	0.000554	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000123	0.000554	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000122	0.000553	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000118	0.000535	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000116	0.000524	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000115	0.000519	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000115	0.000518	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000113	0.000511	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000111	0.000502	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000111	0.000501	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	0.000111	0.000501	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.00011	0.000496	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000109	0.000492	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000109	0.000492	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000106	0.000478	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000104	0.000472	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000101	0.000457	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	0.000101	0.000454	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—AGT—dilated cardiomyopathy	9.98e-05	0.000451	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	9.93e-05	0.000448	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ADRB1—dilated cardiomyopathy	9.81e-05	0.000443	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	9.49e-05	0.000429	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	9.48e-05	0.000428	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	9.46e-05	0.000427	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	9.4e-05	0.000425	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	9.4e-05	0.000425	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	9.01e-05	0.000407	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	9e-05	0.000407	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	8.74e-05	0.000395	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—AGT—dilated cardiomyopathy	8.61e-05	0.000389	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	8.55e-05	0.000386	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	8.47e-05	0.000382	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AGTR1—dilated cardiomyopathy	8.38e-05	0.000378	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—ADRB2—dilated cardiomyopathy	7.95e-05	0.000359	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.91e-05	0.000357	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	7.85e-05	0.000354	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	7.74e-05	0.000349	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	7.7e-05	0.000348	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—EGFR—dilated cardiomyopathy	7.61e-05	0.000344	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	7.23e-05	0.000327	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RAC1—dilated cardiomyopathy	6.99e-05	0.000316	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.94e-05	0.000313	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—RAF1—dilated cardiomyopathy	6.92e-05	0.000313	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—GPX1—dilated cardiomyopathy	6.91e-05	0.000312	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	6.86e-05	0.00031	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	6.83e-05	0.000308	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	6.76e-05	0.000305	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—CD36—dilated cardiomyopathy	6.73e-05	0.000304	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—AGT—dilated cardiomyopathy	6.68e-05	0.000302	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	6.58e-05	0.000297	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RAC1—dilated cardiomyopathy	6.17e-05	0.000279	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—AGT—dilated cardiomyopathy	6.06e-05	0.000274	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	5.98e-05	0.00027	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	5.93e-05	0.000268	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—AGT—dilated cardiomyopathy	5.89e-05	0.000266	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	5.89e-05	0.000266	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	5.38e-05	0.000243	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	5.33e-05	0.000241	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—AGT—dilated cardiomyopathy	5.09e-05	0.00023	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—GPX1—dilated cardiomyopathy	5.01e-05	0.000226	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—GPX1—dilated cardiomyopathy	5e-05	0.000226	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—CD36—dilated cardiomyopathy	4.88e-05	0.00022	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—CD36—dilated cardiomyopathy	4.87e-05	0.00022	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.75e-05	0.000214	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—RAF1—dilated cardiomyopathy	4.64e-05	0.000209	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—AGT—dilated cardiomyopathy	4.39e-05	0.000198	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—AGT—dilated cardiomyopathy	4.38e-05	0.000198	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	4.1e-05	0.000185	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—RAF1—dilated cardiomyopathy	4.09e-05	0.000185	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	3.55e-05	0.000161	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	3.53e-05	0.000159	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	3.52e-05	0.000159	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	3.46e-05	0.000156	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	3.43e-05	0.000155	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	3.18e-05	0.000144	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	3.12e-05	0.000141	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	3.09e-05	0.00014	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	3.01e-05	0.000136	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	2.93e-05	0.000132	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—EGFR—dilated cardiomyopathy	2.81e-05	0.000127	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	2.64e-05	0.000119	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	2.42e-05	0.000109	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	2.32e-05	0.000105	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	2.26e-05	0.000102	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	2.04e-05	9.2e-05	CbGpPWpGaD
